Avenue Therapeutics

Avenue Therapeutics

  • Founded: 2015
  • Location: New York, NY
  • Employee range: 1 - 10
  • Funding: $3.25M stock Jan 2023; $12M stock Oct 2022



job board

Short description:

IV Tramadol

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Avenue Therapeutics is seeking to develop and commercialize therapies to treat central nervous system (CNS) disorders. There is a large unmet patient and market need in the CNS therapeutic space. Key to Avenue’s clinical development strategy is delivering near-term milestones that can build near-term value. Avenue’s portfolio includes two clinical stage programs, IV Tramadol for acute postoperative surgical pain and BAER-101 for epilepsy and acute anxiety. In particular, BAER-101 was licensed from AstraZeneca and can target the large market of patients with drug-resistant epilepsy. Through additional acquisitions in the CNS disease spaces, Avenue aims to further expand their pipeline.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com